Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
14 nov. 2024 07h00 HE
|
Nuvectis Pharma, Inc.
NXP800 demonstrated single agent activity New dosing schedule successfully minimized thrombocytopenia Fort Lee, NJ, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:...
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
05 nov. 2024 07h00 HE
|
Nuvectis Pharma, Inc.
Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal...
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
23 oct. 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
07 oct. 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
05 sept. 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
06 août 2024 08h28 HE
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
16 mai 2024 08h30 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative...
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
07 mai 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDAData presented at the...
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
08 avr. 2024 08h30 HE
|
Nuvectis Pharma, Inc.
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells...
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
19 mars 2024 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...